Recent Drug Approvals
Researchers are working to develop new and improved therapies for people with Parkinson's disease (PD). There have been many drugs that have been approved to treat Parkinson disease. In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa. Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia in people with Parkinson's, who are taking levodopa. This is the first drug indicated specifically for dyskinesia, which is developed with the long-term usage of levodopa. These newly-approved drugs, with different formulations, are addressing different unmet needs and are expected to drive the Parkinson disease drug market.
The other factors, which are also driving the market, include increasing demand due to the higher prevalence of the disease, new entrants expected to balance generic intrusion, and increasing use of the MAO-B inhibitor.
Generic Competition to Key Therapies
In the coming years, many of the Parkinson’s disease branded drugs are expected to lose their patent. For instance, these patent expirations include Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone). After expiration, the already-approved generic alternatives to these drugs can be marketed at a low price, resulting in competition. According to Novartis, annual report of 2016, the Parkinson’s disease drug business for the United States and Europe were majorly being affected by the availability of generic drugs, such as Exelon (rivastigmine tartrate), in the market. The release of the premium product is expected to face intense competition against the generic alternatives present in the market, which will restrain the global market.
The other restraining factor is the high cost of treatment and absence of revolutionary products in the near future.
Europe Holds the Largest Share of the Market
Geographically, Europe is expected to hold the largest share of the market in 2017 followed by North America, Asia-Pacific and the rest of the world. Europe is also expected to command the Parkinson's disease treatment market. A large share of the European market in this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. Asia is expected to grow at the highest CAGR, during the forecast period.
Key Developments in the Market
- January 2018: Pfizer, the world's third-largest drug maker, announced that it is ending research to discover new medications for Alzheimer's and Parkinson's diseases, due to the high cost involved.
- January 2018: Adamas Pharmaceuticals Inc. launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia.
Reasons to Purchase the Report
- Current and future market outlook for Parkinson’s disease drugs in the developed and emerging markets
- Analyze various perspectives on the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth, during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the market estimate sheet (in Excel)
This report can be customized to meet your requirements..
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Demand Owing to Higher Prevalence of the Disease
6.1.2 Recent Drug Approvals
6.1.3 New Entrants Expected to Balance Generic Intrusion
6.1.4 Increasing Use of the MAO-B Inhibitor
6.2 Market Restraints
6.2.1 Generic Competition to Key Therapies
6.2.2 High Cost of Treatment
6.2.3 Absence of Revolutionary Products in Near Future
6.4 Key Challenges
7. Market Segmentation
7.1 By Mechanism of Action
7.1.1 Dopamine Agonists
220.127.116.11 Carbidopa/levodopa (Sinemet, Sinemet CR, Rytary, Duopa)
18.104.22.168 Apomorphine (Apokyn)
22.214.171.124 Pramipexole (Mirapex, Mirapex ER)
126.96.36.199 Ropinirole (Requip and Requip XL)
188.8.131.52 Rotigotine (Neupro)
184.108.40.206 Benztropine mesylate (Cogentin)
7.1.3 MAO-B inhibitors
220.127.116.11 Selegiline (Eldepryl)
18.104.22.168 Rasagiline (Azilect)
7.1.4 Acetylcholinesterase Inhibitors, Central
22.214.171.124 Donepezil (Aricept)
126.96.36.199 Rivastigmine (Exelon)
188.8.131.52 Galantamine (Razadyne, Razadyne ER)
7.1.5 NMDA Antagonists
184.108.40.206 Memantine (Namenda, Namenda XR)
7.1.6 COMT Inhibitors
220.127.116.11 Tolcapone (Tasmar)
18.104.22.168 Entacapone (Comtan)
22.214.171.124 Carbidopa, Levodopa, and Entacapone (Stalevo)
7.1.7 Selective Serotonin Inverse Agonists (SSIA)
126.96.36.199 Pimavanserin (Nuplazid)
7.2 By Geography
7.2.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 Australia & New Zealand
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.2.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of the Middle East & Africa
7.2.5 South America
220.127.116.11 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Merck & Co. Inc.
9.2 Impax Laboratories Inc.
9.3 AbbVie Inc.
9.4 Mylan NV
9.5 Boehringer Ingelheim
9.6 GlaxoSmithKline PLC
9.7 Somerset Pharmaceuticals Inc.
9.8 Teva Pharmaceuticals
9.10 Novartis AG
9.11 Johnson & Johnson (Janssen)
9.12 Allergan Plc
9.13 Takeda Pharmaceutical Company
9.14 List Not Exhaustive
10. Future of the Market
- Merck & Co. Inc.
- Impax Laboratories Inc.
- Abbvie Inc.
- Mylan Nv
- Boehringer Ingelheim
- Glaxosmithkline Plc.
- Somerset Pharmaceuticals Inc.
- Teva Pharmaceuticals
- Novartis Ag
- Johnson & Johnson (Janssen)
- Allergan Plc